GLP_1 RA Ultrasound Study

N/AEnrolling By InvitationNCT06581120

Children's Hospital Medical Center, Cincinnati100 enrolled

Overview

The purpose of the study is to determine whether patients taking GLP-1 RAs have increased residual (left behind), gastric (stomach), contents due to delayed gastric emptying when following standard preoperative fasting guidelines.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Glucagon Like Peptide-1 (GLP-1 Delayed Gastric Emptying Risk of Aspiration Diabetes Morbid Obesity

Interventions

Glucagon-Like Peptide-1 receptor agonistsDRUG

GLP-1 RAs: Glucagon like peptide-1 receptor agonists, this includes patients who are on Liraglutide, Semaglutide, Dulaglutide and Tirzepatide.Tirzepatide which is a combined GLP-1 RA/glucose-dependent insulinotropic polypeptide (GIP) agonist is included as a part of GLP-1 RAs.

Point of Care Gastric UltrasoundDIAGNOSTIC_TEST

A gastric ultrasound following a standard NPO period to determine gastric contents and risk of aspiration during surgery.

Eligibility

Sex: ALLMin age: 10 YearsMax age: 25 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Body Mass Index over 35 * Type 2 Diabetes * Currently taking GLP01 RA agonist (for GLP 1 group) * Not taking GLP-1 RA agonist (for control group) Exclusion Criteria: * Diagnosis of gastroparesis * patient refusal to participate * Previous gastric bypass or any other gastric surgery * Currently on peritoneal dialysis * Abdominal pathology * Gastro-intestinal obstruction * Pregnancy

Locations (1)

Cincinnati Children's Hospital

Cincinnati, Ohio, United States

Outcomes

Primary Outcomes

Aspiration Risk determined by POGUS

Difference between control group and GLP-1 group. Measured by Gastric contents during Point of Care Gastric Ultrasound.

Time frame: Two years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.